• Something wrong with this record ?

Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study

QD. Do, A. Hásková, L. Radovnická, J. Konečná, E. Horová, CG. Parkin, G. Grunberger, M. Prázný, J. Šoupal

. 2024 ; 26 (1) : 78-84. [pub] 20230925

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000148

Grant support
MH CZ-DRO-VFN64165 Ministry of Health, Czech Republic - conceptual development of research organization, General University Hospital in Prague
Cooperatio Program, research area "Metabolic Diseases", Charles University in Prague

AIM: To compare open-source AndroidAPS (AAPS) and commercially available Control-IQ (CIQ) automated insulin delivery (AID) systems in a prospective, open-label, single-arm clinical trial. METHODS: Adults with type 1 diabetes who had been using AAPS by their own decision entered the first 3-month AAPS phase then were switched to CIQ for 3 months. The results of this treatment were compared with those after the 3-month AAPS phase. The primary endpoint was the change in time in range (% TIR; 70-80 mg/dL). RESULTS: Twenty-five people with diabetes (mean age 34.32 ± 11.07 years; HbA1c 6.4% ± 3%) participated in this study. CIQ was comparable with AAPS in achieving TIR (85.72% ± 7.64% vs. 84.24% ± 8.46%; P = .12). Similarly, there were no differences in percentage time above range (> 180 and > 250 mg/dL), mean sensor glucose (130.3 ± 13.9 vs. 128.3 ± 16.9 mg/dL; P = .21) or HbA1c (6.3% ± 2.1% vs. 6.4% ± 3.1%; P = .59). Percentage time below range (< 70 and < 54 mg/dL) was significantly lower using CIQ than AAPS. Even although participants were mostly satisfied with CIQ (63.6% mostly agreed, 9.1% strongly agreed), they did not plan to switch to CIQ. CONCLUSIONS: The CODIAC study is the first prospective study investigating the switch between open-source and commercially available AID systems. CIQ and AAPS were comparable in achieving TIR. However, hypoglycaemia was significantly lower with CIQ.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000148
003      
CZ-PrNML
005      
20240228100343.0
007      
ta
008      
240109s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/dom.15289 $2 doi
035    __
$a (PubMed)37743832
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Do, Quoc Dat, $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic $d 1994- $7 xx0314623
245    10
$a Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study / $c QD. Do, A. Hásková, L. Radovnická, J. Konečná, E. Horová, CG. Parkin, G. Grunberger, M. Prázný, J. Šoupal
520    9_
$a AIM: To compare open-source AndroidAPS (AAPS) and commercially available Control-IQ (CIQ) automated insulin delivery (AID) systems in a prospective, open-label, single-arm clinical trial. METHODS: Adults with type 1 diabetes who had been using AAPS by their own decision entered the first 3-month AAPS phase then were switched to CIQ for 3 months. The results of this treatment were compared with those after the 3-month AAPS phase. The primary endpoint was the change in time in range (% TIR; 70-80 mg/dL). RESULTS: Twenty-five people with diabetes (mean age 34.32 ± 11.07 years; HbA1c 6.4% ± 3%) participated in this study. CIQ was comparable with AAPS in achieving TIR (85.72% ± 7.64% vs. 84.24% ± 8.46%; P = .12). Similarly, there were no differences in percentage time above range (> 180 and > 250 mg/dL), mean sensor glucose (130.3 ± 13.9 vs. 128.3 ± 16.9 mg/dL; P = .21) or HbA1c (6.3% ± 2.1% vs. 6.4% ± 3.1%; P = .59). Percentage time below range (< 70 and < 54 mg/dL) was significantly lower using CIQ than AAPS. Even although participants were mostly satisfied with CIQ (63.6% mostly agreed, 9.1% strongly agreed), they did not plan to switch to CIQ. CONCLUSIONS: The CODIAC study is the first prospective study investigating the switch between open-source and commercially available AID systems. CIQ and AAPS were comparable in achieving TIR. However, hypoglycaemia was significantly lower with CIQ.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a mladý dospělý $7 D055815
650    _2
$a lidé středního věku $7 D008875
650    12
$a diabetes mellitus 1. typu $x farmakoterapie $7 D003922
650    _2
$a hypoglykemika $x terapeutické užití $7 D007004
650    _2
$a prospektivní studie $7 D011446
650    _2
$a glykovaný hemoglobin $7 D006442
650    _2
$a inzulinové infuzní systémy $7 D007332
650    _2
$a krevní glukóza $7 D001786
650    _2
$a selfmonitoring glykemie $x metody $7 D015190
650    12
$a inzuliny $7 D061385
650    _2
$a inzulin $x terapeutické užití $7 D007328
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hásková, Aneta $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic
700    1_
$a Radovnická, Lucie $u 1st Faculty of Medicine Charles University, Prague, Czech Republic $u Department of Internal Medicine, Masaryk Hospital, Ústí nad Labem, Czech Republic
700    1_
$a Konečná, Judita $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic
700    1_
$a Horová, Eva $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic
700    1_
$a Parkin, Christopher G $u CGParkin Communications, Inc., Henderson, Nevada, USA
700    1_
$a Grunberger, George $u Grunberger Diabetes Institute, Bloomfield Hills, Michigan, USA $1 https://orcid.org/0000000324310532
700    1_
$a Prázný, Martin $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic
700    1_
$a Šoupal, Jan $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic $1 https://orcid.org/000000016041190X $7 xx0224300
773    0_
$w MED00005425 $t Diabetes, obesity and metabolism $x 1463-1326 $g Roč. 26, č. 1 (2024), s. 78-84
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37743832 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240228100338 $b ABA008
999    __
$a ok $b bmc $g 2049061 $s 1209842
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 1 $d 78-84 $e 20230925 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
GRA    __
$a MH CZ-DRO-VFN64165 $p Ministry of Health, Czech Republic - conceptual development of research organization, General University Hospital in Prague
GRA    __
$p Cooperatio Program, research area "Metabolic Diseases", Charles University in Prague
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options